How Amino Acids Enhance LNP mRNA Delivery: A New Direction for mRNA Therapeutics
- Jason Lu
- May 9
- 6 min read
Introduction
How Amino Acids Enhance LNP mRNA Delivery: A New Direction for mRNA Therapeutics
Over the past few years, lipid nanoparticles (LNPs) have become the cornerstone of modern mRNA therapeutics.
From COVID-19 mRNA vaccines to cancer immunotherapy, rare disease treatment, and gene editing, LNPs are now one of the most important delivery platforms for nucleic acid medicines.
But anyone who has worked in drug delivery knows a frustrating reality:
An LNP system that performs beautifully in vitro often performs far less efficiently in vivo.
Traditionally, researchers have tried to solve this problem by optimizing lipid formulations:
designing new ionizable lipids,
modifying PEG-lipid ratios,
adjusting cholesterol composition,
conducting high-throughput screening,
or even using AI-guided lipid discovery.
These approaches remain critically important. However, a recent Science Translational Medicine study introduces a very different perspective:
The bottleneck may not only be the nanoparticle itself, but also the metabolic state of the target cell.
Are Traditional Cell Culture Conditions Truly Physiological?
Most in vitro experiments rely on conventional media such as RPMI or DMEM. These formulations were originally designed decades ago to maximize cell growth—not to mimic the metabolic environment of human plasma.
To address this issue, the researchers used HPLM (Human Plasma-Like Medium), a culture medium designed to better reproduce the metabolite composition of human blood plasma.
What they observed was striking:
When cells were cultured in HPLM, LNP-mediated mRNA delivery efficiency dropped substantially.
Across multiple epithelial cell lines, EGFP expression decreased by roughly 50–80% under HPLM conditions compared with RPMI.
This is one of the most important messages of the study:
The question is no longer simply “How do we optimize LNPs?”
It is also:
Are our in vitro screening systems fundamentally too different from the real human physiological environment?
Multiomic Analysis Identified Amino Acid Metabolism as a Key Factor
The team next performed metabolomic and transcriptomic analyses.
They found that several amino acid–related metabolic pathways were significantly downregulated under HPLM conditions, particularly pathways involving:
methionine,
arginine,
and serine.
This led to a critical question:
If these amino acids were supplemented back into the system, could LNP delivery efficiency be restored?
The answer was yes.
Three Amino Acids Increased LNP mRNA Delivery by 5–20 Fold
The researchers conducted combinatorial amino acid screening and identified an optimized amino acid supplement (AAS) consisting of:
methionine,
arginine,
and serine.
The optimal formulation increased LNP-mediated mRNA expression by up to 18.6-fold.
Importantly, the enhancement was not restricted to a single cell type.
The study demonstrated improved delivery across:
epithelial cells,
mesenchymal stem cells,
and monocytic cells,
with at least ~5-fold enhancement observed broadly across cell types.
The Mechanism: Enhanced Endocytosis Rather Than Enhanced Translation
One of the most interesting parts of the study was the mechanistic investigation.
Using dual-labeled LNPs, the researchers separately tracked:
LNP uptake (DiD signal),
and mRNA expression (EGFP signal).
Their findings showed that AAS primarily enhances:
endocytosis
rather than downstream mRNA translation.
More specifically, the supplement enhanced:
CLIC-mediated endocytosis (clathrin-independent carrier-mediated endocytosis).
This suggests that amino acid supplementation is not simply acting as a nutrient boost. Instead, it transiently alters cellular metabolism and membrane trafficking behavior, making cells more permissive to nanoparticle uptake.
Protein Corona: Another Major Barrier in LNP mRNA Delivery
Cellular metabolism is not the only factor influencing LNP performance in vivo.
Another major concept in nanoparticle delivery is the:
protein corona
Once nanoparticles enter the bloodstream, plasma proteins rapidly adsorb onto their surfaces.
These proteins may include:
albumin,
apolipoproteins,
complement proteins,
and immunoglobulins.
This adsorbed protein layer forms what is known as the protein corona.
In reality, cells often do not interact with the “original” nanoparticle design. Instead, they interact with a biologically redefined nanoparticle coated with plasma proteins.
Protein corona formation can influence:
particle size,
surface charge,
biodistribution,
RES clearance,
cellular uptake,
and immune activation.
For years, protein corona has been considered one of the major reasons why nanoparticle performance in vitro poorly predicts performance in vivo.
What makes this study particularly interesting is that it expands the discussion beyond extracellular interactions.
It suggests that even if protein corona shapes the external identity of nanoparticles,
the internal metabolic state of the target cell still critically determines whether the nanoparticle can be efficiently internalized.
This represents an important conceptual shift:
Future LNP optimization may require not only material engineering, but also metabolic and systems-level biological engineering.
In Vivo Results: Not Just Brighter Signals, But Better Therapeutic Outcomes
The study’s most compelling aspect is that it did not stop at cell culture experiments.
The researchers tested:
intramuscular injection,
intratracheal delivery,
and intravenous administration
in mouse models.
Across all delivery routes, coadministration of AAS significantly enhanced mRNA expression in vivo.
Acute Liver Injury Model: Improved Survival Outcomes
The team further evaluated therapeutic efficacy using an acetaminophen (APAP) overdose–induced acute liver injury model.
When growth hormone (GH) mRNA-LNPs were coadministered with AAS, the treated animals showed:
increased serum GH expression,
reduced ALT levels,
decreased liver necrosis,
lower inflammatory cytokine expression,
and dramatically improved survival.
In the lethal liver injury model:
LNP alone rescued only ~33% of mice,
whereas LNP + AAS rescued all treated animals.
This demonstrates that enhanced LNP mRNA delivery may translate into genuine therapeutic benefits—not merely stronger reporter signals.
Even More Impressive: In Vivo Gene Editing Efficiency
The researchers also tested CRISPR-Cas9 delivery.
Using LNPs carrying:
Cas9 mRNA,
and EGFP-targeting guide RNA,
they performed intratracheal gene editing in the lung.
The results were remarkable:
LNP alone achieved ~20–30% editing efficiency,
while LNP + AAS achieved ~85–90% efficiency.
For the gene editing field, this is highly significant because delivery efficiency is often the true bottleneck limiting therapeutic translation.
Why This Study Matters
The importance of this work extends beyond identifying three amino acids.
It fundamentally reframes how we think about delivery optimization.
Historically, the field focused heavily on:
ionizable lipid chemistry,
PEG-lipid engineering,
cholesterol composition,
and AI-driven nanoparticle screening.
But future LNP mRNA delivery optimization may also require attention to:
cellular metabolism,
endocytosis states,
tissue microenvironments,
immune interactions,
and protein corona dynamics.
In other words:
The next generation of mRNA therapeutics may involve optimizing not only the nanoparticle itself, but also the biological state of the target cell.
Limitations of the Study
Despite its exciting findings, this remains a preclinical study.
Several key questions still need to be addressed:
safety and biodistribution of AAS across tissues,
risk of off-target uptake,
applicability across different LNP platforms,
compatibility with receptor-targeted nanoparticles,
and long-term dosing safety.
In addition, the study still relied on HPLM supplemented with 10% FBS, which does not fully replicate the true in vivo physiological environment.
Further validation in large animal and translational models will be essential.
LuTra Consulting: From LNP mRNA Delivery to Translational Strategy
At LuTra Consulting, we closely follow advances in:
mRNA therapeutics,
gene editing,
LNP delivery,
translational medicine,
and AI-enabled biotech strategy.
Many biotech companies today can build nanoparticle platforms.
But the real challenge is often not:“Can we formulate an LNP?”
Instead, the harder questions are:
How do we improve in vivo efficacy?
How do we reduce toxicity?
How do we improve manufacturability?
How do we bridge the gap between in vitro and in vivo performance?
How do we build physiologically relevant screening systems?
This study is important because it reminds us:
Delivery optimization is not only a chemistry problem—it is also a biology problem.
LuTra Consulting focuses on:
mRNA/LNP platform strategy,
delivery technology landscape analysis,
translational R&D planning,
biotech scientific communication,
U.S. biotech market insights,
and cross-functional scientific strategy.
If your team is developing nucleic acid therapeutics, gene editing technologies, or nanoparticle delivery systems, we would be happy to connect.
Final Thoughts
This Science Translational Medicine paper may represent an important turning point for the LNP mRNA delivery field.
Over the past decade, we primarily optimized nanoparticles.
Over the next decade, we may begin optimizing:
nanoparticles,
cellular metabolism,
tissue environments,
and immune interactions simultaneously.
Because ultimately, delivery success may depend not only on:“what particle we designed,”
but also on:
whether the target cell is biologically prepared to receive it.
References
Chen K. et al. Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle–mediated mRNA delivery in preclinical models. Science Translational Medicine. 2026. DOI: 10.1126/scitranslmed.adx4097
Cantor JR. The rise of physiologic media. Trends in Cell Biology. 2019.
Cantor JR. et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase. Cell. 2017.
Wilhelm S. et al. Analysis of nanoparticle delivery to tumours. Nature Reviews Materials. 2016.
Paunovska K. et al. A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation. Nano Letters. 2018.
Ngo W. et al. Identifying cell receptors for the nanoparticle protein corona using genome screens. Nature Chemical Biology. 2022.
Gong N. et al. Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery.Nature Materials. 2024.
Rennick JJ. et al. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nature Nanotechnology. 2021.
Zhao Y. et al. Rational design of lipid nanoparticles: Overcoming physiological barriers for selective intracellular mRNA delivery. Current Opinion in Chemical Biology. 2024.
Gillmore JD. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine. 2021.
Comments